[SCHEDULE 13G] NeuroOne Medical Technologies Corporation SEC Filing

Rhea-AI Filing Summary

Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach disclosed beneficial ownership of 4,000,000 common shares of NeuroOne Medical Technologies, representing 8.03% of the company’s common stock. The filing states Bleichroeder LP is an investment adviser and that these shares are held in the ordinary course of business for its clients.

The reporting persons report sole voting and sole dispositive power over the 4,000,000 shares and no shared voting or dispositive power. The filing also notes the stake was not acquired to change or influence control of the issuer and that client beneficiaries retain rights to dividends and sale proceeds.

Positive

• Material minority position disclosed: 4,000,000 shares representing 8.03% of common stock, which is above the 5% reporting threshold
• Held in ordinary course by an investment adviser: Bleichroeder LP states holdings are for clients and not acquired to influence control

Negative

• None.

Insights

Financial Analyst

Material 8.03% stake disclosed by an investment adviser; notable for shareholder register and potential market interest.

The Schedule 13G reports a significant minority position of 4,000,000 shares (8.03%) held by Bleichroeder-affiliated reporting persons, with sole voting and dispositive power claimed. As an investment adviser filing under the appropriate Schedule 13G treatment, the filer states the position is held in the ordinary course for clients and not for control. For investors, this is a transparency event that confirms a sizable, passive client position but does not by itself signal strategic control or corporate action.

Corporate Governance Expert

Disclosure clarifies governance standing: a material passive stake with no shared control reported.

The filing clarifies the reporting parties' classifications and authorities: Bleichroeder LP is identified as an investment adviser and the holders claim sole voting and dispositive powers over the reported shares while asserting no intent to influence control. Item responses indicate no group arrangements and Item 6 explains clients, not the adviser, ultimately receive dividends and sale proceeds. This reduces immediate governance risk while placing a visible, potentially influential shareholder on the registry.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

NEUROONE MEDICAL TECHNOLOGIES ORD

(Name of Issuer)

Common Shares

(Title of Class of Securities)

64130M209

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 64130M209

1

Names of Reporting Persons

Bleichroeder LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,000,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,000,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,000,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.03 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 64130M209

1

Names of Reporting Persons

Bleichroeder Holdings LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,000,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,000,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,000,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.03 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 64130M209

1

Names of Reporting Persons

Andew Gundlach

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,000,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,000,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,000,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.03 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: NEUROONE MEDICAL TECHNOLOGIES ORD
(b)	Address of issuer's principal executive offices: 7599 ANAGRAM DR, EDEN PRAIRIE, MN 55344
Item 2.
(a)	Name of person filing: Bleichroeder Holdings LLC Bleichroeder LP Andrew Gundlach
(b)	Address or principal business office or, if none, residence: 1345 Avenue of the Americas, 47th Floor New York, NY 10105
(c)	Citizenship: Bleichroeder Holdings LLC and Bleichroeder LP: Delaware, USA Andrew Gundlach: United States
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 64130M209
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See cover page.
(b)	Percent of class: See cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See cover page.
	(ii) Shared power to vote or to direct the vote: See cover page.
	(iii) Sole power to dispose or to direct the disposition of: See cover page.
	(iv) Shared power to dispose or to direct the disposition of: See cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 4,000,000 shares, or 8.03% of the common stock believed to be outstanding as a result of acting as investment adviser to various clients. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99.2
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bleichroeder LP

Signature:	Andew Gundlach
Name/Title:	President and CEO
Date:	08/12/2025

Bleichroeder Holdings LLC

Signature:	Andew Gundlach
Name/Title:	President and CEO
Date:	08/12/2025

Andew Gundlach

Signature:	Andew Gundlach
Name/Title:	President and CEO
Date:	08/12/2025

Exhibit Information

Exhibit 1: Agreement of the Reporting Persons Exhibit 2: Subsidiary Information

FAQ

What stake did Bleichroeder report in NeuroOne (NMTC)?

The reporting persons disclosed beneficial ownership of 4,000,000 shares, representing 8.03% of NeuroOne's common stock.

Who filed the Schedule 13G for NMTC?

The filing lists Bleichroeder LP, Bleichroeder Holdings LLC, and Andrew Gundlach as the reporting persons.

How are the shares held according to the filing?

The filing states the shares are held in the ordinary course of business by an investment adviser and for clients who retain rights to dividends and sale proceeds.

Does the filer claim voting or dispositive power over the shares?

Yes. The filing reports sole voting power and sole dispositive power for 4,000,000 shares and no shared voting or dispositive power.

Does the Schedule 13G indicate an intent to change control of NMTC?

The filing certifies the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

How are the reporting persons classified in the filing?

Bleichroeder LP is identified as an investment adviser (IA); Bleichroeder Holdings LLC and Andrew Gundlach are classified as HC on the cover information.